Patents Assigned to Creighton University
-
Patent number: 12246058Abstract: The disclosure provides polypeptides and pharmaceutical compositions thereof. Such polypeptides can be useful, for example, in treating pain in a subject. In some embodiments, the polypeptides are useful for treating neuropathic and/or inflammatory pain.Type: GrantFiled: January 20, 2021Date of Patent: March 11, 2025Assignee: Creighton UniversityInventor: Shashank Dravid
-
Patent number: 12146191Abstract: Systems and methods for detection and classification of IMP carbapenemases are described. In an aspect, sets of PCR primers associated with specific probes can be used to identify specific families of IMP ?-lactamases and utilize multiple primer sets to identify all IMP variants via real-time PCR assays. The sets of PCR primers can also be coupled with a fluorescent dye to detect a broad range of the IMP variants.Type: GrantFiled: May 3, 2023Date of Patent: November 19, 2024Assignee: Creighton UniversityInventors: Nancy D. Hanson, Hayden Smith, Stacey Morrow
-
Patent number: 11685766Abstract: Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3? heterodimerization or CDC25A binding to 14-3-3?. A peptide composition embodiment includes, but is not limited to, at least one of a first targeting peptide comprising a structure of Ac-Gln-Arg-Gln-Asn-Ser-(PO32?)-Ala-Pro-Ala-Arg-NH2 (SEQ ID NO: 4) and a second targeting peptide comprising a structure of Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO32?)-Trp-Ala-Gly-NH2 (SEQ ID NO: 5), and a third targeting peptide comprising a modification of or a substituted derivative of the peptide of SEQ ID NO: 4 or SEQ ID NO: 5.Type: GrantFiled: May 7, 2021Date of Patent: June 27, 2023Assignees: Creighton University, Nutech VenturesInventors: Laura Hansen, Sandor Lovas, Nicholas Palermo
-
Patent number: 11608328Abstract: The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.Type: GrantFiled: February 21, 2020Date of Patent: March 21, 2023Assignees: Creighton University, Colorado State University Research FoundationInventors: E. Jeffrey North, Amitkumar Navinchandra Pandya, Mary C. Jackson, Wei Li, Mercedes Gonzalez-Juarrero
-
Patent number: 11154619Abstract: Provided herein is a small molecule delivery system with illumination-induced small molecule release based on the binary combination of charged liposomes containing small molecules and oppositely charged conjugates of a peptide with a photosensitizer attached to one end of peptide chain, providing binding to liposomes and their permeabilization upon light illumination.Type: GrantFiled: February 20, 2018Date of Patent: October 26, 2021Assignee: Creighton UniversityInventors: Igor Meerovich, Alekha Dash, Michael Nichols, David Smith
-
Patent number: 11058655Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.Type: GrantFiled: January 6, 2020Date of Patent: July 13, 2021Assignees: Vireo Systems, Inc., Creighton UniversityInventors: Thomas McDonald, Kristen Drescher
-
Patent number: 10907217Abstract: Methods for differentiating E. coli sequence type 131 are described. In one implementation, a method that employs example techniques in accordance with the present disclosure for determining E. coli sequence type 131 includes amplifying a gene target in the presence of a fluorescent reporter dye; exposing the gene target and the fluorescent reporter dye to an increasing temperature gradient to denature and reduce the helicity of a double-stranded oligo of the gene target; recording fluctuations in fluorescence using a High Resolution Melting analysis (HRM)-capable thermocycler; and producing a melt curve unique to the gene target.Type: GrantFiled: September 1, 2016Date of Patent: February 2, 2021Assignee: Creighton UniversityInventors: Nancy D. Hanson, Lucas Harrison
-
Publication number: 20200331897Abstract: The present application provides detectable compounds useful for identifying compounds that bind (e.g., inhibit) MmpL3. Methods of identifying compounds that bind and/or inhibit MmpL3 are also provided.Type: ApplicationFiled: February 21, 2020Publication date: October 22, 2020Applicants: Creighton University, Colorado State University Research FoundationInventors: Jeffrey North, Amitkumar Navinchandra Pandya, Mary Jackson, Wei Li, Mercedes Gonzalez-Juarrero
-
Publication number: 20200197343Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.Type: ApplicationFiled: January 6, 2020Publication date: June 25, 2020Applicants: Vireo Systems, Inc., Creighton UniversityInventors: Thomas McDonald, Kristen Drescher
-
Patent number: 10613011Abstract: A method of performing a diffusion test includes clamping a membrane to a body such that a first surface of the membrane is in fluid communication with an interior chamber of the body and a second surface of the membrane is exposed to ambient air, flowing a substance through the ambient air such that at least a portion of the substance lands on the second surface while the membrane is vertically oriented, and determining a concentration of the substance in the interior chamber after some of the substance has diffused through the membrane.Type: GrantFiled: March 13, 2017Date of Patent: April 7, 2020Assignee: Creighton UniversityInventors: Daniel Munt, Alekha Dash
-
Patent number: 10525027Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.Type: GrantFiled: May 15, 2018Date of Patent: January 7, 2020Assignees: Vireo Systems, Inc., Creighton UniversityInventors: Thomas McDonald, Kristen Drescher
-
Patent number: 10420759Abstract: The present disclosure relates to pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) and its derivatives and pharmaceutically acceptable salts thereof, use of these compounds as a medicament, and for the manufacture of a medicament for treating or delaying the onset or development of pulmonary hypertension.Type: GrantFiled: April 7, 2017Date of Patent: September 24, 2019Assignee: Creighton UniversityInventors: Yaping Tu, Yan Xie, Peter Abel
-
Patent number: 10383848Abstract: Provided herein are indole-2-carboxamide compounds useful for the treatment of non-tuberculosis bacterial infections. Exemplary compounds provided herein are useful for the treatment of non-tuberculosis mycobacterial infections. Methods for preparing the indole-2-carboxamide compounds are also provided.Type: GrantFiled: August 4, 2017Date of Patent: August 20, 2019Assignees: Creighton University, Colorado State University Research FoundationInventors: Jeffrey North, Mary C. Jackson
-
Patent number: 10213397Abstract: Disclosed are methods and pharmaceutical compositions for treating cardiomyopathies. The disclosed methods and pharmaceutical compositions may be used for treating lamin A/C (LMNA)-related dilated cardiomyopathies (DCM) in a subject in need thereof. The disclosed methods may utilize and the disclosed pharmaceutical compositions may include an effective amount of a modulator of microtubule polymerization such as colchicine.Type: GrantFiled: December 21, 2017Date of Patent: February 26, 2019Assignees: Northwestern University, Creighton UniversityInventors: Jane Elizabeth Wilcox, Joshua D. Prenosil
-
Patent number: 10179134Abstract: An antiretroviral composition that gels upon heating and can be administered prophylactically prior to exposure to a retrovirus following sexual intercourse, and methods of using the same.Type: GrantFiled: July 31, 2013Date of Patent: January 15, 2019Assignee: Creighton UniversityInventors: Chris Destache, Abhijit Date, Annemarie Shibata
-
Publication number: 20180250255Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.Type: ApplicationFiled: May 15, 2018Publication date: September 6, 2018Applicants: Vireo Systems, Inc., Creighton UniversityInventors: Thomas McDonald, Kristen Drescher
-
Publication number: 20180169040Abstract: Disclosed are methods and pharmaceutical compositions for treating cardiomyopathies. The disclosed methods and pharmaceutical compositions may be used for treating lamin A/C (LMNA)-related dilated cardiomyopathies (DCM) in a subject in need thereof. The disclosed methods may utilize and the disclosed pharmaceutical compositions may include an effective amount of a modulator of microtubule polymerization such as colchicine.Type: ApplicationFiled: December 21, 2017Publication date: June 21, 2018Applicants: Northwestern University, Creighton UniversityInventors: Jane Elizabeth Wilcox, Joshua D. Prenosil
-
Patent number: 9993452Abstract: The present invention is directed to novel anti-inflammatory immunomodulators including creatinine or a creatinine salt, for example, creatinine hydrochloride. The present invention is also directed to methods for treating inflammation and inducing an immunomodulatory response. In particular, the anti-inflammatory immunomodulators are useful for treating an inflammatory condition or an autoimmune disease.Type: GrantFiled: December 7, 2015Date of Patent: June 12, 2018Assignees: Vireo Systems, Inc., Creighton UniversityInventors: Thomas McDonald, Kristen Drescher
-
Patent number: 9925185Abstract: The present disclosure relates to methods of treating acquired sensorineural hearing loss and/or ototoxicity in mammals by administering quinoxaline or a pharmaceutically acceptable derivative thereof. In implementations, quinoxaline and its derivatives can decrease cochlear hair cell damage and/or stimulate cochlear hair cell proliferation. In some implementations, quinoxaline can be administered as a pre-treatment prior to, or in conjunction with, exposure to ototoxic pharmaceutical agent(s) and/or acoustic trauma to prevent or decrease cochlear hair cell cytotoxicity and/or stimulate cochlear hair cell proliferation. In other implementations, quinoxaline can be administered as a treatment following exposure to ototoxic pharmaceutical agent(s) and/or acoustic trauma to stimulate cochlear hair cell proliferation.Type: GrantFiled: December 3, 2015Date of Patent: March 27, 2018Assignee: Creighton UniversityInventor: Sonia M. Rocha-Sanchez
-
Patent number: 9700541Abstract: A method and a composition are utilized to affect mitochondrial functions on a seizure-genic brain region. In one aspect, the disclosure comprises methods of treating seizures. Seizures are a transient symptom of abnormal excessive or synchronous neuronal activity in the brain. Seizures may manifest as a wild thrashing movement, a brief loss of awareness, an alteration in mental state, tonic or clonic movements, convulsions, a full body slump, and various other psychic symptoms such as déjà vu or jamais vu. Recurrent, unprovoked seizures are medically known as epilepsy. In one implementation, the method of treating a seizure includes administering a composition that restores mitochondrial function to a seizure-genic brain region. In some embodiments, the composition can include ascorbic acid, vitamin E, and pyruvate.Type: GrantFiled: June 12, 2013Date of Patent: July 11, 2017Assignee: Creighton UniversityInventors: Kristina A. Simeone, Timothy A. Simeone